The weekly litigation news digest is live. Subscribe now
Efficacious Treatment Of Nsclc And Predictive Clinical Marker Of The Responsiveness Of A Tumour To A Treatment - EP2994125
The patent EP2994125 was granted to Boehringer Ingelheim on Aug 1, 2018. The application was originally filed on May 8, 2014 under application number EP14721905A. The patent is currently recorded with a legal status of "Revoked".
EP2994125
- Application Number
- EP14721905A
- Filing Date
- May 8, 2014
- Status
- Revoked
- Mar 6, 2020
- Publication Date
- Aug 1, 2018
- External Links
- Slate, Register, Google Patents
Patent Summary
Designing an individual therapy for a subject suffering from non-small cell lung cancer (NSCLC) as well as to a clinical indicator (hereinafter designated as clinical marker) useful as predictive variable of the responsiveness of a NSCLC tumour to a treatment. The therapy includes treatment with a vascular endothelial growth factor inhibitor or with a vascular endothelial growth factor receptor inhibitor.
Patent Family
Patent Oppositions (4)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (16) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents